{
    "title": "Translating molecular advances in fragile X syndrome into therapy: a review.",
    "doc_id": "24813413",
    "writer": "Hagerman RJ",
    "year": "2014",
    "summary": "Fragile X syndrome is an inherited disease with cognitive, behavioral, and neurologic manifestations, resulting from a single genetic mutation. A variety of treatments that target individual symptoms of fragile X syndrome are currently ut â€¦",
    "abstract": "Fragile X syndrome is an inherited disease with cognitive, behavioral, and neurologic manifestations, resulting from a single genetic mutation. A variety of treatments that target individual symptoms of fragile X syndrome are currently utilized with limited efficacy. Research in animal models has resulted in the development of potential novel pharmacologic treatments that target the underlying molecular defect in fragile X syndrome, rather than the resultant symptoms. This review describes recent advances in our understanding of the molecular basis of fragile X syndrome and summarizes the ongoing clinical research programs.",
    "link": "https://pubmed.ncbi.nlm.nih.gov/24813413/",
    "clean_text": "translating molecular advances in fragile x syndrome into therapy a review fragile x syndrome is an inherited disease with cognitive behavioral and neurologic manifestations resulting from a single genetic mutation a variety of treatments that target individual symptoms of fragile x syndrome are currently ut fragile x syndrome is an inherited disease with cognitive behavioral and neurologic manifestations resulting from a single genetic mutation a variety of treatments that target individual symptoms of fragile x syndrome are currently utilized with limited efficacy research in animal models has resulted in the development of potential novel pharmacologic treatments that target the underlying molecular defect in fragile x syndrome rather than the resultant symptoms this review describes recent advances in our understanding of the molecular basis of fragile x syndrome and summarizes the ongoing clinical research programs"
}